The Burden of HPV-Associated Anogenital Cancers

Current Oncology Reports

Volumn 16, Issue 9, 2014, Pages 1-11

  Wakeham, Katie ^a   Kavanagh, Kimberley ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Anal cancer; Cervical cancers; Human papillomavirus; Penile cancer; Vaginal cancer; Vulvar cancer

Indexed keywords

WART VIRUS VACCINE;

ANOGENITAL CANCER; ANUS CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; DISEASE ASSOCIATION; GENITAL TRACT CANCER; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PREVALENCE; REVIEW; RISK FACTOR; SQUAMOUS CELL CARCINOMA; UNITED KINGDOM; UTERINE CERVIX CANCER; VACCINATION; VAGINA CANCER; VIRUS TRANSMISSION; VULVA CANCER; WART VIRUS;

EID: 84957431097     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-014-0402-4     Document Type: Review

References (101)

1. International Agency for Research on Cancer. GLOBOCAN 2012. In: Cervical cancer estimated incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 4 May 2014.
2. McCredie MR et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2006;9(5):425–34.
3. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine. 2006;24 Suppl 3:S11–25.
4. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120:885–90.
5. International Collaboration of Epidemiological Studies of Cervical Cancer. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006;118(6):1481–95.
6. Wallin KL et al. A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer. 2002;101:371–4.
7. Palefsky JM. Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr Opin Oncol. 2003;15(5):382–8.
8. Castellsague X et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med. 2002;346:1105–12.
9. International Agency for Research on Cancer. World Cancer Report 2008. http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/index.php. Accessed on 4 May 2014.
10. Information Service Division, Scotland. Cancer incidence and mortality in Scotland by site/type of cancer, sex and year of diagnosis/registration of death: 2002-2011. http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/. Accessed 4 May 2014.
11. Information Service Division, Scotland. Scottish Cervical Screening Programme. http://www.isdscotland.org/Health-Topics/Cancer/Cervical-Screening/. Accessed on 4 May 2014.
12. Hill GB, Adelstein AM. Cohort mortality from carcinoma of the cervix. Lancet. 1967;2(7516):605–6.
13. Bray F et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2191–9.
14. Bray F et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev. 2005;14(3):677–86.
15. Sankaranarayanan R et al. An overview of cancer survival in Africa, Asia, the Caribbean and Central America: the case for investment in cancer health services. IARC Sci Publ. 2011;162:257–91.
16. Quinn MA et al. Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S43–103.
17. Maranga IO et al. Analysis of factors contributing to the low survival of cervical cancer patients undergoing radiotherapy in Kenya. PLoS One. 2013;8(10):e78411.
18. Siegel R et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
19. Daling JR et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101:270–80.
20. Melbye M, Sprogel P. Aetiological parallel between anal cancer and cervical cancer. Lancet. 1991;338:657–9.
21. Frisch M et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337(19):1350.
22. Daling JR et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med. 1987;317:973–7.
23. Edgren G, Sparen P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol. 2007;8:311–6.
24. Rabkin CS et al. Second primary cancers following anal and cervical carcinoma: evidence of shared etiologic factors. Am J Epidemiol. 1992;136(1):54.
25. Frisch M et al. Malignancies that occur before and after anal cancer: clues to their etiology. Am J Epidemiol. 1994;140:12–9.
26. Holly EA et al. Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst. 1989;81:1726–31.
27. Palefsky JM, Rubin M. The epidemiology of anal human papillomavirus and related neoplasia. Obstet Gynecol Clin N Am. 2009;36(1):187–200.
28. Palefsky J. Human papillomavirus and anal neoplasia. Curr HIV/AIDS Rep. 2008;5:78–85.
29. Silverberg MJ et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54:1026–34.
30. Crum-Cianflone NF et al. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS. 2010;24:535–43.
31. Bower M et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr. 2004;37:1563–5.
32. Diamond C et al. Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex Transm Dis. 2005;32:314–20.
33. Sunesen KG et al. Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005. Int J Cancer. 2010;127:675–84.
34. Adami J et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89(7):1221–7.
35. Johnson LG et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer. 2004;101:281–8.
36. Brewster DH, Bhatti LA. Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975-2002. Br J Cancer. 2006;95:87–90.
37. Frisch M et al. Trends in incidence of anal cancer in Denmark. BMJ. 1993;306:419–22.
38. Jin F et al. Trends in anal cancer in Australia, 1982-2005. Vaccine. 2011;29:2322–7.
39. Nielsen A et al. Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978-2008. Int J Cancer. 2012;130:1168–73.
40. Robinson D et al. An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in southeast England. Br J Cancer. 2009;100:527–31.
41. Simard EP et al. Trends in the occurrence of high-grade anal intraepithelial neoplasia in San Francisco: 2000-2009. Cancer. 2013;119:3539–45.
42. Amirian ES et al. Anal cancer incidence and survival: comparing the greater San-Francisco bay area to other SEER cancer registries. PLoS One. 2013;8:e58919.
43. Gatta G et al. Survival from rare cancer in adults: a population-based study. Lancet Oncol. 2006;7:132–40.
44. Hernandez BY et al. Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. Cancer. 2008;113:2883–91.
45. Ornellas AA. Management of penile cancer. J Surg Oncol. 2008;97(3):199–200.
46. Maden C et al. History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J Natl Cancer Inst. 1993;85:19–24.
47. Daling JR et al. Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer. 2005;116:606–16.
48. Engels EA et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20:1645–54.
49. Lajous M et al. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1710–6.
50. Bleeker MC et al. Penile lesions and human papillomavirus in male sexual partners of women with cervical intraepithelial neoplasia. J Am Acad Dermatol. 2002;47(3):351–7.
51. Partridge JM et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis. 2007;196(8):1128–36.
52. Chokunonga E et al. Trends in the incidence of cancer in the black population of Harare, Zimbabwe 1991-2010. Int J Cancer. 2013;133:721–9.
53. Wabinga HR et al. Trends in the incidence of cancer in Kampala, Uganda 1991-2010. Int J Cancer. 2014;135(2):432–9.
54. Wabinga HR et al. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. Br J Cancer. 2000;82:1585–92.
55. Ficarra V et al. Prognostic factors in penile cancer. Urology. 2010;76(2 Suppl 1):S66.
56. Bruni L, et al. Human papillomavirus and related diseases report. L'Hospitalet de Llobregat: ICO Information Centre on HPV and Cancer; 2014.
57. Daling JR et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol. 2002;84:263–70.
58. Strander B et al. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ. 2007;335:1077.
59. Engels EA et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891–901.
60. Gunderson CC, et al. A contemporary analysis of epidemiology and management of vaginal intraepithelial neoplasia. Am J Obstet Gynecol. 2013;208:410.e1–6.
61. Gunderson CC et al. Vaginal cancer: the experience from 2 large academic centers during a 15-year period. J Low Genit Tract Dis. 2013;17:409–13.
62. Cheng D et al. Wide local excision (WLE) for vaginal intraepithelial neoplasia (VAIN). Acta Obstet Gynecol Scand. 1999;78(7):648.
63. Aho M et al. Natural history of vaginal intraepithelial neoplasia. Cancer. 1991;68(1):195.
64. Hellman K et al. Clinical and histopathologic factors related to prognosis in primary squamous cell carcinoma of the vagina. Int J Gynecol Cancer. 2006;16:1201–11.
65. Tran PT et al. Prognostic factors for outcomes and complications for primary squamous cell carcinoma of the vagina treated with radiation. Gynecol Oncol. 2007;105:641–9.
66. Joura EA et al. Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med. 2000;45:613–5.
67. Madsen BS et al. Risk factors for invasive squamous cell carcinoma of the vulva and vagina—population-based case-control study in Denmark. J Int Cancer. 2008;122:2827–34.
68. Jones RW et al. Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol. 1997;90:448–52.
69. Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS. 2009;4:52–6.
70. van Seters M et al. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol. 2005;97:645–51.
71. Judson PL et al. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol. 2006;107:1018–22.
72. Srodon M et al. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol. 2006;30:1513–8.
73. Conley LJ et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet. 2002;359:108–13.
74. Burger MP et al. The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients. Gynecol Oncol. 1995;57:327–34.
75. Gadducci A et al. Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol. 2006;60:227–41.
76. International Agency for Research on Cancer, monographs on the evaluation of carcinogenic risk to humans, 2007. In: Monograph on human papillomavirus, volume 90. http://monographs.iarc.fr/ENG/Monographs/vol90/index.php. Accessed 18 June 2014.
77. Clifford G et al. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006;24 Suppl 3:S26–34.
78. De Vuyst H et al. Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa. Int J Cancer. 2012;131:949–55.
79. Houlihan CF et al. Prevalence of human papillomavirus in adolescent girls before reported sexual debut. J Infect Dis. 2014. doi:10.1093/infdis/jiu20.
80. Winer RL et al. Detection of genital HPV types in fingertip samples from newly sexually active female university students. Cancer Epidemiol Biomarkers Prev. 2010;19:1682–5.
81. af Geijersstam V et al. Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969-1989. Int J Cancer. 1998;76:341–4.
82. Laukkanen P et al. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol. 2003;84:2105–9.
83. Mercer CH et al. Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the national surveys of sexual attitudes and lifestyles (Natsal). Lancet. 2013;382:1781–94.
84. Kangas I et al. A comparison of sexual behaviour and attitudes of healthy adolescents in a Danish high school in 1982, 1996, and 2001. Popul Health Metrics. 2004;2:5.
85. Winer RL et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354:2645–54.
86. Gray RH et al. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis. 2010;201:1455–62.
87. Serwadda D et al. Circumcision of HIV-infected men: effects on high-risk human papillomavirus infections in a randomized trial in Rakai, Uganda. J Infect Dis. 2010;201:1463–9.
88. Kitchener HC et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10(7):672.
89. Ronco G et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524.
90. Sankaranarayanan R et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet. 2007;370:398–406.
91. Shastri SS et al. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. Bull World Health Organ. 2005;83:186–94.
92. Franco EL et al. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006;24 Suppl 3:S171–7.
93. Smyczek P et al. Anal intraepithelial neoplasia: review and recommendations for screening and management. Int J STD AIDS. 2013;24(11):843–51.
94. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915.
95. Garland SM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928.
96. Malagon T et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:781–9.
97. Kavanagh K et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014;110:2804–11.
98. Palefsky JM et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365:1576–85.
99. Wigle J et al. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects. Vaccine. 2013;31(37):3811–7.
100. Stanley M. HPV vaccination in boys and men. Hum Vaccin Immunother. 2014. doi:10.4161/hv.29137.
101. The Scottish Parliament. Petitions, PE01477: Gender neutral Human Papillomavirus vaccination, 2013.http://www.scottish.parliament.uk/GettingInvolved/Petitions/petitionPDF/PE01477.pdf. Accessed 17 June 2014.